<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472858</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001/Donafenib-101</org_study_id>
    <nct_id>NCT04472858</nct_id>
  </id_info>
  <brief_title>A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/II, Multicenter,Open-label,Dose-Escalation and Expansion Study of CS1001 in Combination With Donafenib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
      effect of CS1001 in combination with Donafenib in patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the dose limiting toxicity (DLT)</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose(MTD)</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the recommended dose of phase II</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate as determined by the Invertigator using RECIST V1.1</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-CS1001 antibody</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(100mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(100mg BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(200mg BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(RP2D),hepatocellular carcinoma(HCC) patients will be assign</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(RP2D),Head and neck squamous cell carcinoma(HNSCC) patients will be assign</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS1001(1200mg Q3W)+Donafenib(RP2D),Endometrial carcinoma patients will be assign</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>In the dose escalation part, the dose levels of Donafenib will be escalated folowing a modified 3+3 dose escalation scheme.
Dose escalation 1:100 mg once a day;Dose escalation 2:100 mg twice a day;Dose escalation 3:200 mg twice a day.</description>
    <arm_group_label>Dose Escalation 1</arm_group_label>
    <arm_group_label>Dose Escalation 2</arm_group_label>
    <arm_group_label>Dose Escalation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>In the dose expansion part, patients will be assigned to different groups based on their tumor types and treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.</description>
    <arm_group_label>Dose Expansion 1</arm_group_label>
    <arm_group_label>Dose Expansion 2</arm_group_label>
    <arm_group_label>Dose Expansion 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days</description>
    <arm_group_label>Dose Escalation 1</arm_group_label>
    <arm_group_label>Dose Escalation 2</arm_group_label>
    <arm_group_label>Dose Escalation 3</arm_group_label>
    <arm_group_label>Dose Expansion 1</arm_group_label>
    <arm_group_label>Dose Expansion 2</arm_group_label>
    <arm_group_label>Dose Expansion 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fully understand this study and voluntarily sign ICF;

          -  18 to 75 years old (including 18 and 75 years old), male or female;

          -  Subjects with advanced solid tumors, including:

        Phase I study:

        subjects with advanced solid tumors confirmed by histology or cytology that are not
        suitable for surgical resection, or have failed or tolerated standard treatment, or have no
        standard treatment. Including but not limited to hepatocellular carcinoma (HCC), head and
        neck squamous cell carcinoma (HNSCC) and endometrial cancer.

        Phase II study:

        Cohort A: Patients with hepatocellular carcinoma clinically diagnosed or diagnosed with
        pathological histology/cytology according to the &quot;Diagnosis and Treatment of Primary Liver
        Cancer&quot; (Ministry of Health 2017 Edition) have at least one measurable lesion, inoperable
        or metastatic liver Cell carcinoma. Hepatocyte patients who have not previously received
        systemic treatment (systemic chemotherapy, molecular targeted therapy or tumor
        immunotherapy). The time between disease progression, recurrence or metastasis and the last
        treatment interval is at least 6 months.

        Cohort B: HNSCC subjects with advanced metastatic or recurrent HNSCC diagnosed by
        histopathology or cytology, HNSCC subjects who have previously received intolerance or
        disease progression with first-line system treatment.

        Cohort C: patients with advanced metastatic or recurrent endometrial cancer diagnosed by
        histopathology, and endometrial cancer subjects who have previously received first-line
        systemic treatment intolerance or disease progression.

          -  Participant must have at least one measurable lesion by RECIST 1.1;

          -  ECOG performance status score of 0 or 1;

          -  Life expectancy â‰¥ 3 months;

          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             result.

          -  Either Female or male participants must agree to use adequate contraceptive measures
             from signing informed consent and for 180 days after last investigational product
             administration.

        Exclusion Criteria:

          -  Any history of active autoimmune diseases or autoimmune diseases; patients with
             vitiligo or asthma that has been completely relieved in childhood, and patients who do
             not need any intervention after adulthood can be included;

          -  Participants with any condition that impairs their ability to take oral medication,
             such as lack of physical integrity of the upper gastrointestinal tract or
             malabsorption syndrome.

          -  Patients with uncontrolled pleural effusion, pericardial effusion, or ascites
             requiring repeated drainage and need to retain a catheter;

          -  Human immunodeficiency virus (HIV) antibody positive;

          -  Patients who are simultaneously infected with hepatitis B virus and hepatitis C virus;

          -  Lactating women. If they are willing to stop breastfeeding, they can also be included
             in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

